You are here: Home: Audio Program Guide: BCU 1 | 2006 Audio: BCU 1 | 2006

  Go to interview with Paul Goss, MD, PhD
Go to interview with Charles E Geyer Jr, MD
Go to interview with Peter A Kaufman, MD
Go to interview with Joyce O’Shaughnessy, MD
Go to interview with Aman U Buzdar, MD
Go to interview with Clifford Hudis, MD
Go to interview with Kathy D Miller, MD
Go to interview with Professor John F R Robertson, MB, ChB, BSc, MD
 

To listen to individual tracks now, click the icon. To download tracks to a CD, right-click the icon.

     
Paul E Goss, MD, PhD
Director of Breast Cancer Research
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts
 Click here to download the entire interview		 MP3
Track 1 Introduction by Neil Love, MD
Track 2 MA17: Extended adjuvant therapy with letrozole in postmenopausal women
Track 3 MA17: Switching to letrozole after placebo
Track 4 Use of aromatase inhibitors as initial adjuvant therapy by clinical investigators
Track 5 MA17: Summary of the updated results
Track 6 Reduction in the risk of contralateral breast cancer with aromatase inhibitors

Track 7 Risk of recurrence after hormonal therapy
Track 8 Evaluating survival in the adjuvant aromatase inhibitor trials
Track 9 Assessing the potential side effects associated with hormonal therapy
Track 10 Impact of aromatase inhibitors on bone mineral density
Track 11 Selection of an aromatase inhibitor as initial adjuvant therapy
Track 12 Optimizing adjuvant hormonal therapy
Track 13 Duration of adjuvant therapy with an aromatase inhibitor
Track 14 Delayed adjuvant therapy
Track 15 Extended adjuvant letrozole in women with ER-positive, PR-negative disease
Track 16 Optimizing aromatase inhibitors in the treatment and prevention of breast cancer
Charles E Geyer Jr, MD
Director of Medical Affairs
National Surgical Adjuvant Breast and Bowel Project
Director of Breast Medical Oncology
Allegheny General Hospital
Pittsburgh, Pennsylvania
Click here to download the entire interview 		   
Track 1 Introduction by Dr Love
Track 2 Cardiac toxicity with adjuvant trastuzumab
Track 3 Clinical use of adjuvant trastuzumab based on the patient’s post-AC left ventricular ejection fraction
Track 4 Clinical use of adjuvant trastuzumab in a patient with low-risk disease
Track 5 Impact of adjuvant trastuzumab on distant recurrence rate
Track 6 Future adjuvant trials combining trastuzumab with lapatinib or bevacizumab
Track 7 Clinical use of delayed adjuvant trastuzumab
Track 8 Proposed NSABP trial evaluating the duration of adjuvant therapy with an aromatase inhibitor
Track 9 NSABP-B-40: Neoadjuvant chemotherapy trial
Track 10 NSABP-B-41: Phase II randomized trial of neoadjuvant trastuzumab
Track 11 NSABP-B-39: Trial of conventional versus partial breast irradiation
       

Peter A Kaufman, MD
Associate Professor of Medicine
Section of Hematology/Oncology
Dartmouth-Hitchcock Medical Center
Comprehensive Breast Care Program Norris Cotton Cancer Center
Lebanon, New Hampshire
Click here to download the entire interview

   
Track 1 Introduction by Dr Love
Track 2 Overview of the adjuvant trastuzumab trials
Track 3 NCCTG-N9831: Concurrent versus sequential adjuvant trastuzumab
Track 4 Initiating trastuzumab therapy after discontinuation of an adjuvant anthracycline

Track 5 Clinical use of adjuvant trastuzumab in patients with node-negative disease
Track 6 Use of adjuvant trastuzumab in older patients
Track 7 Incorporation of adjuvant trastuzumab in a dose-dense chemotherapy regimen
Track 8 Adjuvant trastuzumab monotherapy in older patients
Track 9 Delayed adjuvant trastuzumab
Track 10 Controversies in HER2 testing
Track 11 Common questions regarding the clinical use of adjuvant trastuzumab
Track 12 Future trials of adjuvant trastuzumab
Track 13 Impact of adjuvant trastuzumab data on the treatment of metastatic disease
Track 14 Trastuzumab in combination with liposomal doxorubicin or capecitabine
Track 15 Clinical trials for patients with HER2-negative disease
       

Meet The Professors: Joyce O’Shaughnessy, MD
Co-Director, Breast Cancer
Research Program
Baylor-Charles A Sammons Cancer Center
US Oncology
Dallas, Texas
Click here to download the entire interview

   
Track 1 Introduction by Dr Love
Track 2 Adjuvant trial comparing docetaxel/ cyclophosphamide versus doxorubicin/ cyclophosphamide
Track 3 Adjuvant trial comparing doxorubicin/ cyclophosphamide followed by every three-week paclitaxel versus doxorubicin/paclitaxel followed by weekly paclitaxel
Track 4 Clinical trials combining taxanes and capecitabine in the adjuvant and metastatic settings

Track 5 Trials of adjuvant dose-dense nanoparticle albumin-bound (nab) paclitaxel
Track 6 Adjuvant chemotherapy for low- and high-risk patients in the clinical setting
Track 7 Dosing and scheduling of capecitabine in the metastatic setting
Track 8 Adjuvant nab paclitaxel in clinical practice
       

Meet The Professors: Aman U Buzdar, MD
Professor of Medicine
Deputy Chairman, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Click here to download the entire interview

   
Track 1 Introduction by Dr Love
Track 2 Aromatase inhibitors versus tamoxifen as initial adjuvant endocrine therapy in postmenopausal patients
Track 3 Safety profiles of the aromatase inhibitors
Track 4 Risk of cancer-specific mortality after recurrence

Track 5 Identifying patients who may benefit from initial adjuvant therapy with tamoxifen
Track 6 Tolerability of aromatase inhibitors versus tamoxifen
       

Meet The Professors: Clifford Hudis, MD
Chief, Breast Cancer Medicine Service
Solid Tumor Division, Memorial
Sloan-Kettering Cancer Center
New York, New York
Click here to download the entire interview

   
Track 1 Introduction by Dr Love
Track 2 Rationale for dose-dense chemotherapy
Track 3 Retrospective analysis of adjuvant chemotherapy trials CALGB-8541, 9344 and 9741
Track 4 Impact of adjuvant chemotherapy on patients with ER-positive disease

Track 5 Selecting adjuvant chemotherapy based on ER status and risk of recurrence
Track 6 Rationale for increasing the frequency of dose-dense therapy
Track 7 Evaluating dose-dense AC/nab paclitaxel
Track 8 Economic impact of newer treatment alternatives
Track 9 Rationale for dose-dense therapy in patients with ER-positive disease
       

Meet The Professors: Kathy D Miller, MD
Sheila D Ward Scholar of Medicine
Associate Professor of Medicine
Department of Hematology/Oncology
Indiana University School of Medicine
Indianapolis, Indiana
Click here to download the entire interview

   
Track 1 Introduction by Dr Love
Track 2 Rationale and design of the E2100 trial: Paclitaxel with or without bevacizumab as firstline treatment for metastatic disease
Track 3 Combining bevacizumab with paclitaxel versus capecitabine
Track 4 Identifying patients most likely to benefit from bevacizumab

Track 5 Bevacizumab in the treatment of inflammatory breast cancer
Track 6 Combining capecitabine and bevacizumab in clinical practice for metastatic disease
Track 7 Metronomic chemotherapy plus bevacizumab
       

Meet The Professors: Professor John F R Robertson, MB, ChB, BSc, MD
Professor of Surgery
Head of Academic Division of Breast Surgery
University of Nottingham City Hospital
Nottingham, United Kingdom
Click here to download the entire interview

   
Track 1 Introduction by Dr Love
Track 2 Development of fulvestrant
Track 3 Clinical trials of fulvestrant for patients with disease progression after aromatase inhibitors
Track 4 Fulvestrant in treatment of premenopausal patients with metastatic disease

Track 5 Rationale for combining fulvestrant with an aromatase inhibitor
Track 6 Whether to continue an aromatase inhibitor when adding fulvestrant for disease progression
Track 7 LHRH agonist plus endocrine therapy for premenopausal patients in the adjuvant setting